Effects of vitamin D supplementation on alveolar macrophage gene expression: preliminary results of a randomized, controlled trial

Alicia K Gerke, Alejandro A Pezzulo, Fan Tang, Joseph E Cavanaugh, Thomas B Bair, Emily Phillips, Linda S Powers, Martha M Monick, Alicia K Gerke, Alejandro A Pezzulo, Fan Tang, Joseph E Cavanaugh, Thomas B Bair, Emily Phillips, Linda S Powers, Martha M Monick

Abstract

Background: Vitamin D deficiency has been implicated as a factor in a number of infectious and inflammatory lung diseases. In the lung, alveolar macrophages play a key role in inflammation and defense of infection, but there are little data exploring the immunomodulatory effects of vitamin D on innate lung immunity in humans. The objective of this study was to determine the effects of vitamin D supplementation on gene expression of alveolar macrophages.

Methods: We performed a parallel, double-blind, placebo-controlled, randomized trial to determine the effects of vitamin D on alveolar macrophage gene expression. Vitamin D3 (1000 international units/day) or placebo was administered to adults for three months. Bronchoscopy was performed pre- and post-intervention to obtain alveolar macrophages. Messenger RNA was isolated from the macrophages and subjected to whole genome exon array analysis. The primary outcome was differential gene expression of the alveolar macrophage in response to vitamin D supplementation. Specific genes underwent validation by polymerase chain reaction methods.

Results: Fifty-eight subjects were randomized to vitamin D (n = 28) or placebo (n = 30). There was a marginal overall difference between treatment group and placebo group in the change of 25-hydroxyvitaminD levels (4.43 ng/ml vs. 0.2 ng/ml, p = 0.10). Whole genome exon array analysis revealed differential gene expression associated with change in serum vitamin D levels in the treated group. CCL8/MCP-2 was the top-regulated cytokine gene and was further validated.

Conclusions: Although only a non-significant increased trend was seen in serum vitamin D levels, subjects treated with vitamin D supplementation had immune-related differential gene expression in alveolar macrophages.

Trial registration: ClinicalTrials.org: NCT01967628.

Figures

Figure 1
Figure 1
Subjects enrollment.
Figure 2
Figure 2
Treatment effect for 25-hydroxyvitamin D (25(OH)D) levels by treatment group (vitamin D versus placebo) (p = 0.10).
Figure 3
Figure 3
Comparison of pre and post supplementation mRNA of candidate genes in subjects treated with vitamin D whose 25-hydroxyvitamin D level rose greater than 5 ng/ml (measured by polymerase chain reaction).

References

    1. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50:194–200. doi: 10.1016/j.jcv.2010.12.006.
    1. Martineau AR. Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis. Proc Nutr Soc. 2012;71:84–89. doi: 10.1017/S0029665111003326.
    1. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134:1129–1140. doi: 10.1017/S0950268806007175.
    1. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax. 2010;65:215–220. doi: 10.1136/thx.2009.120659.
    1. Youssef DA, Miller CW, El-Abbassi AM, Cutchins DC, Cutchins C, Grant WB, Peiris AN. Antimicrobial implications of vitamin D. Dermatoendocrinol. 2011;3:220–229. doi: 10.4161/derm.3.4.15027.
    1. Hewison M. Vitamin D, and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010;321:103–111. doi: 10.1016/j.mce.2010.02.013.
    1. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–1773. doi: 10.1126/science.1123933.
    1. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microb. 2009;6:231–243. doi: 10.1016/j.chom.2009.08.004.
    1. Graff JW, Powers LS, Dickson AM, Kim J, Reisetter AC, Hassan IH, Kremens K, Gross TJ, Wilson ME, Monick MM. Cigarette smoking decreases global microRNA expression in human alveolar macrophages. PloS One. 2012;7:e44066. doi: 10.1371/journal.pone.0044066.
    1. Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine. 2010;77:552–557. doi: 10.1016/j.jbspin.2010.09.018.
    1. Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012;67:10–17. doi: 10.1111/j.1398-9995.2011.02711.x.
    1. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol. 2008;181:7090–7099.
    1. Jorde R, Witham M, Janssens W, Rolighed L, Borchhardt K, de Boer IH, Grimnes G, Hutchinson MS. Vitamin D supplementation did not prevent influenza-like illness as diagnosed retrospectively by questionnaires in subjects participating in randomized clinical trials. Scand J Infect Dis. 2012;44:126–132. doi: 10.3109/00365548.2011.621446.
    1. Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, Sandler RS, Bresalier RS, Goodman M, Bostick RM, Baron JA. Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. Clin Infect Dis. 2013;57:1384–1392. doi: 10.1093/cid/cit549.
    1. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255–1260. doi: 10.3945/ajcn.2009.29094.
    1. Blaszczyk J, Coillie EV, Proost P, Damme JV, Opdenakker G, Bujacz GD, Wang JM, Ji X. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry. 2000;39:14075–14081. doi: 10.1021/bi0009340.
    1. Liu H, Liu Z, Chen J, Chen L, He X, Zheng R, Yang H, Song P, Weng D, Hu H, Fan L, Xiao H, Kaufmann SH, Ernst J, Ge B. Induction of CCL8/MCP-2 by mycobacteria through the activation of tlr2/pi3k/akt signaling pathway. PloS One. 2013;8:e56815. doi: 10.1371/journal.pone.0056815.
    1. Maddocks S, Scandurra GM, Nourse C, Bye C, Williams RB, Slobedman B, Cunningham AL, Britton WJ. Gene expression in HIV-1/mycobacterium tuberculosis co-infected macrophages is dominated by M. Tuberculosis. Tuberculosis. 2009;89:285–293. doi: 10.1016/j.tube.2009.05.003.
    1. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, Ravn P. TBNet. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J. 2008;32:1607–1615. doi: 10.1183/09031936.00055508.
    1. Riek AE, Oh J, Bernal-Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J Steroid Biochem Mol Biol. 2013;136:309–312.
    1. Gao D, Trayhurn P, Bing C. 1,25-dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes. 2013;37:357–365. doi: 10.1038/ijo.2012.53.
    1. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009;179:843–850. doi: 10.1164/rccm.200804-567OC.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever